Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)

NCT03087032 on ClinicalTrials.gov · last registry update 2025-01-13

An unusually large phase 4: 164 participants, more than double the 75 typical for the stage. Its estimated completion date, 15 January 2025, has passed with no update to the record. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: The First Affiliated Hospital of Xiamen University
Sponsor type: Other
Enrollment: 164
Started: 2019-01-10
Primary completion: 2025-01-15 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

the proportion of patients with HbA1c < 7.0% without experiencing hypoglycemia and without weight gain,with a superiority margin of 3%

Conditions studied

Type 2 Diabetes Patients · Overweight and Obesity · Hyperglycaemia (Diabetic)

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.